


## PHARMACEUTICAL 2020



## OptiNose Inc. Rank 232 of 362





## PHARMACEUTICAL 2020



## OptiNose Inc. Rank 232 of 362

The relative strengths and weaknesses of OptiNose Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OptiNose Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 117% points. The greatest weakness of OptiNose Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 164% points.

The company's Economic Capital Ratio, given in the ranking table, is -267%, being 36% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	168,060
Cost of Goods Sold	5,294
Intangible Assets	0
Liabilities, Current	36,139
Liabilities, Non-Current	74,531
Other Assets	1,538
Other Compr. Net Income	9.0
Other Expenses	9,623
Other Liabilities	397
Other Net Income	-4,829
Property and Equipment	3,052
Research and Development	20,783
Revenues	34,631
Selling, General and Administrative Expense	104,155

Output Variable	Value in 1000 USD
Assets	172,650
Liabilities	111,067
Expenses	139,855
Stockholders Equity	61,583
Net Income	-110,053
Comprehensive Net Income	-110,048
Economic Capital Ratio	-267%

